Logo

Qiagen Licenses HandyLab Extraction Technology

Apr 17, 2009

NEW YORK (GenomeWeb News) – HandyLab said this week that Qiagen has licensed the firm's extraction technology for use in the sample preparation part of its human papillomavirus assays.

Ann Arbor, Mich.-based HandyLab said its extraction technology would be used with the HPV molecular diagnostic tests on Qiagen's QIAensemble and QIAsymphony random access platforms. Financial and other terms of the license were not disclosed.

HandyLab is a privately-held molecular diagnostics company developing products for the decentralization of nucleic acid testing.

Filed under

Diagnostics
Sample Preparation
Infectious Disease
HandyLab
HPV
extraction technology
Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.